A post-hoc analysis of the ODYSSEY OUTCOMES (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab) trial found that baseline Lp(a) predicted the risk of MACE after recent ACS (9). Here, LPA is linked to acute coronary syndrome.